Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Resverlogix Corp > Screening
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by toinv261on Dec 28, 2021 12:09pm
238 Views
Post# 34265556

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Screening

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ScreeningSorry jkj.

As long as Don is CEO there will not be any successful business conducted unless the science such as Covid is a complete blockbuster, and that does not seem likely since Don pulled the wool over our eyes once again in December.

Every effort they make seems feeble and second rate.

Ever since the Global Chinese Financial Forum in September 2020 Don has been misleading us in the extreme (to say it kindly). Don neither has the education, financial background, biotech experience and nor does he appear to have credibility in financial markets. Without a trusted and competent CEO RVX is proving to be a very difficult challenge for investors.

I too feel I need apabetalone for my health but It won't be available on the market for many years, sadly, IMHO.

Still we must keep our hopes up. Wishing you good health and a Happy New Year. It is an extremely sad example of the Peter Principle in action.
GLTA
Toinv
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities